The biotechnology company specializes in delivering small molecules, proteins, antibodies, nucleic acids, and gene vectors specifically to target organs using lung-directed hitchhiked therapies. This approach enhances treatment efficacy and reduces drug toxicity for patients with primary pulmonary disorders and lung cancer.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Targeted drug delivery to the lungs is challenging due to the lungs' complex anatomy and defense mechanisms. Traditional systemic drug administration often results in off-target effects and limited drug concentrations in the lungs, reducing efficacy and increasing toxicity. Effective treatment of pulmonary disorders and lung cancer requires precise and efficient drug delivery to the affected tissues.
Solution
The company develops lung-directed hitchhiked therapies to deliver various therapeutic agents, including small molecules, proteins, antibodies, nucleic acids, and gene vectors, specifically to target organs via the lungs. This approach leverages the lungs' natural transport mechanisms to enhance drug accumulation in the target tissues while minimizing systemic exposure and off-target effects. By precisely targeting the lungs, the therapies aim to improve treatment outcomes for patients with primary pulmonary disorders and lung cancer, offering enhanced efficacy and reduced drug toxicity.
Target Audience
The primary target audience includes patients with primary pulmonary disorders and lung cancer, as well as pharmaceutical companies seeking innovative drug delivery solutions for lung-related diseases.
Features
- Lung-directed delivery system for targeted drug administration.
- Versatile platform capable of delivering small molecules, proteins, antibodies, nucleic acids, and gene vectors.
- Enhanced drug accumulation in target tissues within the lungs.
- Minimized systemic exposure and off-target effects.
- Improved treatment efficacy for pulmonary disorders and lung cancer.
- Reduced drug toxicity compared to traditional systemic administration.